• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ALX Oncology Holdings Inc. - Common Stock (NQ: ALXO )

    1.620 +0.140 (+9.46%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,165,199
    Open 1.510
    Bid (Size) 1.590 (6)
    Ask (Size) 1.610 (1)
    Prev. Close 1.480
    Today's Range 1.510 - 1.670
    52wk Range 1.190 - 17.82
    Shares Outstanding 40,869,135
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
    From ALX Oncology
    Via GlobeNewswire

    Performance

    YTD
    -88.87%
    -88.87%
    1 Month
    +25.58%
    +25.58%
    3 Month
    -18.59%
    -18.59%
    6 Month
    -75.27%
    -75.27%
    1 Year
    -89.47%
    -89.47%

    More News

    Read More
    ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces November Investor Conference Participation
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
    From ALX Oncology
    Via GlobeNewswire
    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Via Benzinga
    ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
    Via InvestorPlace
    ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
    From ALX Oncology
    Via GlobeNewswire
    Crude Oil Moves Lower; Moderna Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Nasdaq Surges 1%; Meta Posts Upbeat Earnings
    Via Benzinga
    Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
    Via Benzinga
    Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
    Via InvestorPlace
    ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.